Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling
OwnerDonald P. Bottaro, Megan Peach +2inventors
InventorsDonald P. Bottaro, Megan Peach, Marc Nicklaus, Nelly Tan
Life of this patent
Estimating the term…
Abstract
Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met obtained by virtual screening, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are provided. Methods of making derivatives and analogs of c-Met inhibitors and methods of use thereof are provided. Formula (I)
Claims13
A compound that is 9-(2,3-dichloro-phenyl)-2,6,7-trihydroxy-xanthen-3-one, or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising at least one pharmaceutically acceptable carrier or excipient and 9-(2,3-dichloro-phenyl)-2,6,7-trihydroxy-xanthen-3-one.
A method for treating a mammal having a neoplastic disease,
- wherein the treatment delays the onset of symptoms, complications, or biochemical indicia of the disease;
- alleviates the symptoms of the disease, arrests further development of the disease;
- or inhibits further development of the disease;
- wherein the neoplastic disease is characterized by a c-Met mutation or an overexpression of c-Met, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I:
- or a pharmaceutically acceptable salt thereof,
- wherein
- R1 and R2 are each independently H, —CN, S, O, N, F, —CH2—OH, —OH, C1-C4 alkyl, amine, or ethanone, and at least one of R1 and R2 is —CN, S, O, N, or F;
- R3 is H;
- C1-C4 alkyl optionally substituted with halo or sulfonate;
- phenyl, phenoxy, or phenoxyalkyl, each optionally substituted with one or two substituents selected from hydroxyl, alkoxy, alkyl, halo, acetamido, acetamido alkoxy, carboxyl, and optionally-substituted amino;
- indolyl;
- pyridinyl;
- furanyl;
- thiophenyl;
- benzo[1,3]dioxolyl;
- or morpholinoalkyl, phenylalkyl or naphthylalkyl, each optionally substituted with alkyl, halo, or haloalkyl;
- R4 and R5 are each independently H;
- —CN;
- S;
- O;
- N;
- F;
- OH;
- C1-C4 alkyl;
- amine;
- ethanone;
- phenyl optionally substituted with hydroxyl, alkyl, or halo;
- or morpholinoalkyl, and at least one of R4 and R5 is —CN, S, O, N, F, or OH;
- R6 is O or N—R7;
- and
- R7 and R8 are each independently H;
- C1-C4 alkyl;
- hydroxyalkyl;
- carboxyalkyl;
- phenyl optionally substituted with one or more substituent selected from hydroxyl, alkoxy, carboxyl, halo, and acetamide-oxy;
- phenylamido;
- phenylamido carboxyl;
- phenylalkyl;
- phenylalkenyl;
- phenylhydrazonoalkyl;
- morpholinoalkyl;
- piperidine-proprionyl optionally substituted with carboxyl;
- or chromen-5-one optionally substituted with alkyl, dialkyl, or amino;
- and
- R9, R10, and R11 are each independently H, lower alkyl, or halo.
Dependencies are inferred from the claim text.